

# Adrian P Bracken

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3136571/publications.pdf>

Version: 2024-02-01

52  
papers

9,758  
citations

147566

31  
h-index

189595

50  
g-index

53  
all docs

53  
docs citations

53  
times ranked

13336  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. <i>Genes and Development</i> , 2006, 20, 1123-1136.	2.7	1,098
2	EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. <i>EMBO Journal</i> , 2003, 22, 5323-5335.	3.5	1,052
3	Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity. <i>EMBO Journal</i> , 2004, 23, 4061-4071.	3.5	778
4	The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. <i>Genes and Development</i> , 2007, 21, 525-530.	2.7	775
5	A model for transmission of the H3K27me3 epigenetic mark. <i>Nature Cell Biology</i> , 2008, 10, 1291-1300.	4.6	656
6	E2Fs regulate the expression of genes involved in differentiation, development, proliferation, and apoptosis. <i>Genes and Development</i> , 2001, 15, 267-285.	2.7	654
7	The Polycomb Group Protein Suz12 Is Required for Embryonic Stem Cell Differentiation. <i>Molecular and Cellular Biology</i> , 2007, 27, 3769-3779.	1.1	628
8	Polycomb group proteins: navigators of lineage pathways led astray in cancer. <i>Nature Reviews Cancer</i> , 2009, 9, 773-784.	12.8	537
9	E2F target genes: unraveling the biology. <i>Trends in Biochemical Sciences</i> , 2004, 29, 409-417.	3.7	497
10	H3K79 Methylation Profiles Define Murine and Human MLL-AF4 Leukemias. <i>Cancer Cell</i> , 2008, 14, 355-368.	7.7	494
11	Retinoic acid expression associates with enhanced IL-22 production by $\hat{\text{T}}^{\text{H}}17$ T cells and innate lymphoid cells and attenuation of intestinal inflammation. <i>Journal of Experimental Medicine</i> , 2013, 210, 1117-1124.	4.2	261
12	Polycomb PHF19 binds H3K36me3 and recruits PRC2 and demethylase NO66 to embryonic stem cell genes during differentiation. <i>Nature Structural and Molecular Biology</i> , 2012, 19, 1273-1281.	3.6	227
13	PRC2 mediated H3K27 methylations in cellular identity and cancer. <i>Current Opinion in Cell Biology</i> , 2015, 37, 42-48.	2.6	193
14	Bypass of senescence by the polycomb group protein CBX8 through direct binding to the INK4A-ARF locus. <i>EMBO Journal</i> , 2007, 26, 1637-1648.	3.5	175
15	Characterization of E2F8, a novel E2F-like cell-cycle regulated repressor of E2F-activated transcription. <i>Nucleic Acids Research</i> , 2005, 33, 5458-5470.	6.5	150
16	The H3K36me2 Methyltransferase Nsd1 Demarcates PRC2-Mediated H3K27me2 and H3K27me3 Domains in Embryonic Stem Cells. <i>Molecular Cell</i> , 2018, 70, 371-379.e5.	4.5	137
17	PRC2.1 and PRC2.2 Synergize to Coordinate H3K27 Trimethylation. <i>Molecular Cell</i> , 2019, 76, 437-452.e6.	4.5	137
18	Dangerous liaisons: interplay between SWI/SNF, NuRD, and Polycomb in chromatin regulation and cancer. <i>Genes and Development</i> , 2019, 33, 936-959.	2.7	127

#	ARTICLE	IF	CITATIONS
19	A Family of Vertebrate-Specific Polycombs Encoded by the LCOR/LCORL Genes Balance PRC2 Subtype Activities. <i>Molecular Cell</i> , 2018, 70, 408-421.e8.	4.5	121
20	CHD5 Is Required for Neurogenesis and Has a Dual Role in Facilitating Gene Expression and Polycomb Gene Repression. <i>Developmental Cell</i> , 2013, 26, 223-236.	3.1	104
21	Polycomb Group Proteins in Cell Cycle Progression and Cancer. <i>Cell Cycle</i> , 2004, 3, 394-398.	1.3	86
22	PRC2 functions in development and congenital disorders. <i>Development (Cambridge)</i> , 2019, 146, .	1.2	85
23	Transcriptional regulation of cellular senescence. <i>Oncogene</i> , 2011, 30, 2901-2911.	2.6	82
24	Dual functionality of <i>cis</i> -regulatory elements as developmental enhancers and Polycomb response elements. <i>Genes and Development</i> , 2017, 31, 590-602.	2.7	71
25	Dynamic Protein Interactions of the Polycomb Repressive Complex 2 during Differentiation of Pluripotent Cells. <i>Molecular and Cellular Proteomics</i> , 2016, 15, 3450-3460.	2.5	60
26	NPAT Expression Is Regulated by E2F and Is Essential for Cell Cycle Progression. <i>Molecular and Cellular Biology</i> , 2003, 23, 2821-2833.	1.1	56
27	Detection of novel germline mutations for breast cancer in non- <i>BRCA1/2</i> families. <i>FEBS Journal</i> , 2015, 282, 3424-3437.	2.2	50
28	Fam60a defines a variant Sin3a-Hdac complex in embryonic stem cells required for self-renewal. <i>EMBO Journal</i> , 2017, 36, 2216-2232.	3.5	45
29	Polycomb group proteins in cell cycle progression and cancer. <i>Cell Cycle</i> , 2004, 3, 396-400.	1.3	43
30	Regulation of Stem Cell Differentiation by Histone Methyltransferases and Demethylases. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 2008, 73, 253-263.	2.0	42
31	The variant Polycomb Repressor Complex 1 component PCGF1 interacts with a pluripotency sub-network that includes DPPA4, a regulator of embryogenesis. <i>Scientific Reports</i> , 2016, 5, 18388.	1.6	38
32	Structural basis for PRC2 engagement with chromatin. <i>Current Opinion in Structural Biology</i> , 2021, 67, 135-144.	2.6	37
33	Simultaneous disruption of PRC2 and enhancer function underlies histone H3.3-K27M oncogenic activity in human hindbrain neural stem cells. <i>Nature Genetics</i> , 2021, 53, 1221-1232.	9.4	36
34	Reassembly and protection of small nuclear ribonucleoprotein particles by heat shock proteins in yeast cells. <i>Rna</i> , 1999, 5, 1586-1596.	1.6	33
35	A chromatin-independent role of Polycomb-like 1 to stabilize p53 and promote cellular quiescence. <i>Genes and Development</i> , 2015, 29, 2231-2243.	2.7	32
36	Protein-truncating variants in moderate-risk breast cancer susceptibility genes: A meta-analysis of high-risk case-control screening studies. <i>Cancer Genetics</i> , 2015, 208, 455-463.	0.2	28

#	ARTICLE	IF	CITATIONS
37	The corepressors GPS2 and SMRT control enhancer and silencer remodeling via eRNA transcription during inflammatory activation of macrophages. <i>Molecular Cell</i> , 2021, 81, 953-968.e9.	4.5	27
38	A "Complex" Issue: Deciphering the Role of Variant PRC1 in ESCs. <i>Cell Stem Cell</i> , 2013, 12, 145-146.	5.2	22
39	Myeloid cell nuclear differentiation antigen controls the pathogen-stimulated type I interferon cascade in human monocytes by transcriptional regulation of IRF7. <i>Nature Communications</i> , 2022, 13, 14.	5.8	18
40	Profiling cancer. <i>Current Opinion in Cell Biology</i> , 2003, 15, 213-220.	2.6	17
41	Delineating transcriptional networks of prognostic gene signatures refines treatment recommendations for lymph node-negative breast cancer patients. <i>FEBS Journal</i> , 2015, 282, 3455-3473.	2.2	12
42	Transcriptomics: Unravelling the biology of transcription factors and chromatin remodelers during development and differentiation. <i>Seminars in Cell and Developmental Biology</i> , 2009, 20, 835-841.	2.3	10
43	Native gel analysis of macromolecular protein complexes in cultured mammalian cells. <i>Proteomics</i> , 2015, 15, 3603-3612.	1.3	8
44	OUP accepted manuscript. <i>Clinical Chemistry</i> , 2022, , .	1.5	5
45	The PCL1-p53 axis promotes cellular quiescence. <i>Cell Cycle</i> , 2016, 15, 305-306.	1.3	3
46	If You Like It Then You Shoulda Put Two "RINGS" on It: Delineating the Roles of vPRC1 and cPRC1. <i>Molecular Cell</i> , 2020, 77, 685-687.	4.5	3
47	Analytical validation of OncoMasTR, a multigene test for predicting risk of distant recurrence in hormone receptor-positive early stage breast cancer. <i>Annals of Oncology</i> , 2018, 29, viii65.	0.6	2
48	Prognostic value of the 6-gene OncoMasTR test in hormone receptor-positive HER2-negative early-stage breast cancer: Comparative analysis with standard clinicopathological factors. <i>European Journal of Cancer</i> , 2021, 152, 78-89.	1.3	2
49	Stem Cell Epigenetics: Looking Forward. <i>Cell Stem Cell</i> , 2014, 14, 706-709.	5.2	1
50	MED 23: a new Mediator of H2B monoubiquitylation. <i>EMBO Journal</i> , 2015, 34, 2863-2864.	3.5	1
51	The 3D Genome: EZH2 Comes into the Fold. <i>Trends in Molecular Medicine</i> , 2019, 25, 362-365.	3.5	1
52	Anticancer innovative therapy: Highlights from the ninth annual meeting. <i>Cytokine and Growth Factor Reviews</i> , 2020, 51, 1-9.	3.2	0